HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Date
2022-08-16Author
Lopez Knowles, E
Cheang, M
Bergamino, M
Tovey, H
Alataki, A
Kilburn, L
Morani, G
Schuster, G
Hills, M
Xiao, H
Smith, I
Bliss, J
Dowsett, M
Type
Journal Article
Metadata
Show full item recordCollections
Research team
Molecular Oncology
Language
eng
Date accepted
2022-07-22
License start date
2022-08-16
Citation
EBioMedicine, 2022,
Publisher
Elsevier